Navigation Links
Discovery points toward anti-inflammation treatment for blinding disease
Date:1/14/2010

The discovery of an inflammatory mediator key to the blinding effects of diabetic retinopathy is pointing toward a potential new treatment, Medical College of Georgia researchers said.

Interleukin-6, known to contribute to the debilitating joint inflammation of rheumatoid arthritis, also helps ignite inflammation of the retina, a first step in a disease that is the leading cause of blindness is working-age adults, MCG researchers reported online in Investigative Ophthalmology & Visual Science.

The finding has the scientists looking at whether an interleukin-6 antibody, which is showing success in treating rheumatoid arthritis, can halt inflammation in mice with diabetic retinopathy. "We expect that this neutralizing antibody can be used to treat diabetic retinopathy in the future," said Dr. Wenbo Zhang, assistant research scientist in MCG's Vascular Biology Center. Drs. Zhang and Modesto Rojas, senior postdoctoral fellow, are co-first authors on the paper.

Angiotensin II, a powerful constrictor of blood vessels, is typically associated with the kidneys where it plays a vital role in regulating blood pressure. The scientists suspect angiotensin II helps promotes wound healing and regulation of pressure within small blood vessels in the eye.

However in diabetes, angiotensin II levels increase in the eye probably in response to high glucose levels and help promote inflammation, spurring remodeling of blood vessels and tissue destruction, Dr. Rojas said. "Vascular inflammation is one of the first steps to inducing the changes in the retina."

MCG scientists have shown interleukin-6 is a needed accomplice whose previously undetectable levels in the eye also increase, said Dr. Ruth Caldwell, cell biologist a the Vascular Biology Center and the Charlie Norwood Veterans Affairs Medical Center and the study's corresponding author.

With the help of interleukin-6, angiotensin II induces white blood cells to stick to the endothelial cells lining blood vessels of the retina, which slows blood flow. The white blood cells also start producing inflammatory and vascular growth factors that cause blood vessel walls to leak and thicken, further constricting blood flow. Retinal cells start dying from the reduced blood and oxygen supplies that result. In response, the body prompts growth of new blood vessels, presumably to help but instead causing more vision impairment.

If the trigger, high glucose, was temporary, these natural responses might help clear damaged cells and protect the eye. "Inflammation is a compensatory mechanism that gets activated as a survival mechanism," Dr. Rojas said. "If it continues, the effect is bad."

"We have known for along time if patients keep their blood sugar under perfect control, they don't have these problems, but that's hard," Dr. Caldwell adds. "That is why it's such a difficult disease."

To examine interleukin-6's role in the destruction, the researchers injected angiotensin II into the vitreous portion of the eyes of mice missing the gene for the inflammatory factor as well as normal mice. The extra angiotensin did little to the retinal vessels of mice lacking interleukin-6 but vessels in the normal mouse retina mimicked the inflammatory reaction found in diabetic retinopathy. When they reintroduced interleukin-6 to the genetically altered mice, the damage mimicked that of the normal mice. "So when we knock out interleukin-6, we can block the effects of angiotensin II," Dr. Caldwell said.

The scientists want to see whether the interleukin-6 antibody can be used to prevent damage by giving it shortly after the onset of diabetes in rodents and as a treatment by using it later in the disease process.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related biology news :

1. Discovery at JGH opens door to new treatments for prostate, brain and skin cancers
2. Discovery of a new molecular mechanism that guides visual nerves towards the brain
3. New discovery by Harvard scientists aims to correct cellular defects leading to diabetes
4. New year, new vitamin C discovery: It cures mice with accelerated aging disease
5. Emerald BioStructures announces discovery of small molecule modulators of PDE4
6. UGA researchers lead team in discovery involving devastating freshwater fish parasite, Ich
7. Discovery makes brain tumor cells more responsive to radiation
8. Discovery of the Jekyll-and-Hyde factors in coral bleaching
9. Rocket science leads to new whale discovery
10. A year after discovery, Congos mother lode of gorillas remains vulnerable
11. Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovery points toward anti-inflammation treatment for blinding disease
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... Orlando, FL (PRWEB) , ... February 21, 2017 ... ... that enables healthcare organizations to build connected digital health applications, announced a partnership ... will enable users to seamlessly connect to many clinical systems while keeping data ...
(Date:2/21/2017)... Francisco, CA (PRWEB) , ... February 21, 2017 ... ... pleased to announce that Dr. Trevor Heritage has joined its executive team to ... revolutionary system designed to provide insights to help improve the diagnosis and treatment ...
(Date:2/21/2017)... ... 21, 2017 , ... VetStem Biopharma, Inc ., announced ... in Poway, California. Based upon 12 years of knowledge gained by following ... VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. This ...
(Date:2/21/2017)... LOS ANGELES , Feb. 21, 2017  Lexus, a returning ... its role as the official and exclusive automobile partner of the ... annual spring race. The 2017 Amgen Tour of ... five-year commitment and feature some of the best professional cycling teams ... , May 14-20. The four-day Amgen Breakaway from Heart ...
Breaking Biology Technology: